翰森制药(03692)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

03692 翰森制药

未开盘 08-10 16:08:05

34.540

+1.620

+4.92%

最高35.000	最低33.240	成交量2,253万
今开33.280	昨收32.920	日振幅5.35%
总市值2,095亿	流通市值2,095亿	总股本60.64亿
成交额7.68亿	换手率0.37%	流通股本60.64亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"03692","market":"HK","secType":"STK","nameCN":"翰森制药","latestPrice":34.54,"timestamp":1786349285005,"preClose":32.92,"halted":0,"volume":22529042,"delay":0,"changeRate":0.0492102065613608,"floatShares":6064000000,"shares":6064000000,"eps":1.0814891847574515,"marketStatus":"未开盘","change":1.62,"latestTime":"08-10 16:08:05","open":33.28,"high":35,"low":33.24,"amount":767612457,"amplitude":0.053463,"askPrice":34.56,"askSize":18000,"bidPrice":34.54,"bidSize":40000,"shortable":3,"etf":0,"ttmEps":1.0803135013533762,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1786411800000},"marketStatusCode":0,"adr":0,"listingDate":1560441600000,"exchange":"SEHK","adjPreClose":32.92,"dividendRate":0.012487,"openAndCloseTimeList":[[1786325400000,1786334400000],[1786338000000,1786348800000]],"volumeRatio":2.539487,"lotSize":2000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/03692","defaultTab":"news","newsList":[{"id":"1113710405","title":"异动解读｜翰森制药盘中上涨3.65%，新药临床获批叠加管线利好持续释放","url":"https://stock-news.laohu8.com/highlight/detail?id=1113710405","media":"行情直击","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1113710405?lang=zh_cn&edition=full","pubTime":"2026-08-10 13:12","pubTimestamp":1786338769,"startTime":"0","endTime":"0","summary":"8月10日，翰森制药盘中上涨3.65%，报34.0港元，成交额3.18亿港元。消息面上，公司近期利好密集。8月6日，公司自主研发的1类新药HS-10582片获中国国家药品监督管理局签发的药物临床试验批准通知书，拟用于治疗成人原发性高胆固醇血症和混合型血脂异常，为公司心血管代谢领域管线再添新品种。里昂维持\"跑赢大市\"评级并将目标价升至42港元，预计明年将有5款新药获批上市，支撑中长期盈利增长。公司中期业绩将于8月26日披露。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03692"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657699773","title":"港股异动 | 翰森制药(03692.HK)午后涨近3% HS-10582片获NMPA签发的药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2657699773","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657699773?lang=zh_cn&edition=full","pubTime":"2026-08-07 13:36","pubTimestamp":1786081013,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1191","BK1583","BK1589","03692"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657334316","title":"翰森制药：新药HS-10582片临床试验获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2657334316","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657334316?lang=zh_cn&edition=full","pubTime":"2026-08-06 19:12","pubTimestamp":1786014720,"startTime":"0","endTime":"0","summary":"8月6日，翰森制药（03692）发布公告，本公司自主研发的1类新药HS-10582片获得中国国家药品监督管理局签发的药物临床试验批准通知书。该药物拟用于治疗成人原发性高胆固醇血症和混合型血脂异常的临床试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608063834021815.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608063834021815.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1191","IBBJ","MDTX","PSYK","03692","BK1583","BK1589","IBBQ","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183420916","title":"翰森制药（03692）自主研发1类新药HS-10582片获NMPA临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1183420916","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1183420916?lang=zh_cn&edition=full","pubTime":"2026-08-06 19:06","pubTimestamp":1786014361,"startTime":"0","endTime":"0","summary":"2026年8月6日，翰森制药集团有限公司（03692）公告称，其自主研发的1类新药HS-10582片已获中国国家药品监督管理局签发的《药物临床试验批准通知书》，拟用于开展治疗成人原发性高胆固醇血症和混合型血脂异常的临床试验。\n公告显示，HS-10582片由翰森制药自主研发，获批后将进入临床阶段研究，为公司在心血管代谢领域的管线布局再添新进展。\n董事会表示，相关临床试验启动后将按照监管要求推进，并于适时披露项目进展。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03692"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160654920","title":"翰森制药（03692）将于2026年8月26日召开董事会审议中期业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1160654920","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1160654920?lang=zh_cn&edition=full","pubTime":"2026-08-04 16:56","pubTimestamp":1785833773,"startTime":"0","endTime":"0","summary":"翰森制药集团有限公司（03692）8月4日公告称，董事会计划于2026年8月26日（星期三）召开会议，审议并批准公司及其附属公司截至2026年6月30日止六个月的中期业绩，并商讨是否宣派中期股息（如有），同时处理其他相关事宜。\n本次董事会由主席钟慧娟女士召集。截至公告日期，董事会成员包括执行董事钟慧娟女士、孙远女士、吕爱锋博士；以及独立非执行董事林国强先生、陈尚伟先生、杨东涛女士和严嘉先生。\n公司表示，将在董事会会议后及时公布经董事会批准的中期业绩及相关决定，供投资者参考。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03692"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191649355","title":"翰森制药7月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1191649355","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1191649355?lang=zh_cn&edition=full","pubTime":"2026-08-04 16:36","pubTimestamp":1785832581,"startTime":"0","endTime":"0","summary":"2026年8月4日，翰森制药公布截至2026年7月31日止当月的股份变动月报表，显示公司股本保持稳定，未发生股份发行或回购活动。根据公告，翰森制药于2026年2月3日发行了于2033年到期的零息可换股债券，金额为港币4,680,000,000元，转股价格为每股港币57.39，若全部转股，最多可发行81,547,308股普通股。本次公告由联席公司秘书郭颖女士签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03692"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122985513","title":"异动解读｜翰森制药盘中下跌3.05%，报31.2港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1122985513","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1122985513?lang=zh_cn&edition=full","pubTime":"2026-08-03 10:01","pubTimestamp":1785722504,"startTime":"0","endTime":"0","summary":"8月3日，翰森制药盘中下跌3.05%，报31.2港元/股，成交额1.09亿港元。翰森制药所在的制药行业中，整体表现偏弱，个股中，石药集团跌2.74%，中国生物制药跌1.39%，恒瑞医药跌1.4%，长风药业跌9.11%，先声药业跌1.62%。翰森制药集团有限公司是一家主要从事一系列药品的研发、生产及销售的投资控股公司。该公司的创新药产品主要应用于抗肿瘤、抗感染、中枢神经系统疾病、代谢及其他治疗领域，主要在国内市场开展业务。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"翰森制药盘中下跌3.05%，报31.2港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03692"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136621193","title":"异动解读｜翰森制药盘中下跌3.04%，报32.5港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1136621193","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1136621193?lang=zh_cn&edition=full","pubTime":"2026-07-30 13:13","pubTimestamp":1785388431,"startTime":"0","endTime":"0","summary":"7月30日，翰森制药盘中下跌3.04%，报32.5港元/股，成交额2.7亿港元。翰森制药所在的制药行业中，整体表现偏弱，个股中，石药集团跌3.31%，中国生物制药跌3.82%，恒瑞医药跌2.23%，凯莱英跌7.39%，东阳光药涨5.17%。翰森制药集团有限公司是一家主要从事药品研发、生产及销售的投资控股公司，创新药产品主要应用于抗肿瘤、抗感染、中枢神经系统疾病、代谢及其他治疗领域，主要在国内市场开展业务。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03692"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655852742","title":"港股异动 | 翰森制药(03692.HK)盘中涨超5% HS-20093骨肉瘤III期临床达主要终点 公司正准备申请上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2655852742","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655852742?lang=zh_cn&edition=full","pubTime":"2026-07-29 15:32","pubTimestamp":1785310362,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1191","BK1583","BK1589","03692"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655839384","title":"智通港股早知道 | 7月份国内风电招标强势回暖 ASMPT(00522)中期股东应占盈利同比增长174.1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2655839384","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655839384?lang=zh_cn&edition=full","pubTime":"2026-07-29 07:17","pubTimestamp":1785280644,"startTime":"0","endTime":"0","summary":"7月份国内风电招标强势回暖市场消息，7月以来国内央国企业主已先后启动约12.7GW的风机招标，分别较今年6月/去年7月提升256%/132%。涉及港股大唐发电。基于对合肥公司发展的良好预期，本公司参与本次公开招标。本次收购事项的完成将进一步提升本公司在合肥公司的持股比例。ASMPT发布2026年中期业绩，股东应占盈利5.89亿港元，同比增长174.1%每股基本盈利1.41港元，拟派中期股息每股0.97港元。ARTEMIS-011研究详细数据预计未来在国际肿瘤学术大会上予以公布。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1473353.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VXUS","LU0417516571.SGD","LU0634319403.HKD","BK1169","BK1183","09858","BK1212","01854","LU0348767384.USD","LU0488056044.USD","BK1237","LU1282649141.HKD","BK1583","LU0348784397.USD","00522","LU0384037296.USD","IE0008369823.USD","LU0540923850.HKD","MCHS","BK1589","01081","LU1813983027.USD","LU0417516738.SGD","BK1507","LU1282649810.SGD","LU0314109678.HKD","LU0348783233.USD","BK1614","LU0417516902.SGD","LU0274383008.USD","SG9999001903.USD","LU0648948544.HKD","LU1328277881.USD","BK1205","SG9999000475.SGD","LU0348735423.USD","BK4585","LU0348825331.USD","BK1121","BK1191","LU1282649067.USD","LU2039709279.SGD","LU0227179875.USD","KCAI","SG9999000459.SGD","LU0348766576.USD","BK4588","03692","BK1587","02039"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151237006","title":"翰森制药（03692）：HS-20093治疗骨肉瘤Ⅲ期关键性试验达到主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=1151237006","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1151237006?lang=zh_cn&edition=full","pubTime":"2026-07-28 18:05","pubTimestamp":1785233139,"startTime":"0","endTime":"0","summary":"2026年7月28日，翰森制药集团有限公司发布自愿公告称，公司自主研发的B7-H3靶向抗体-药物偶联物HS-20093在治疗既往接受至少二线系统治疗后进展或复发的骨肉瘤患者的Ⅲ期关键性临床试验中达到主要终点。与化疗相比，HS-20093在独立评审委员会评估的无进展生存期方面显示具有统计学显著性和临床意义的改善。安全性方面，HS-20093的安全特征与此前研究结果一致，未发现新的安全性信号。ARTEMIS-011研究的详细数据预计将在未来的国际肿瘤学学术大会上公布。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03692"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198068644","title":"翰森制药：HS-20093用于骨肉瘤治疗的III期临床研究已达主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=1198068644","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1198068644?lang=zh_cn&edition=full","pubTime":"2026-07-28 18:02","pubTimestamp":1785232931,"startTime":"0","endTime":"0","summary":"翰森制药宣布，其核心在研药物HS-20093针对骨肉瘤治疗的III期临床研究，已成功达成预设的主要终点。这一里程碑式的进展，标志着该疗法在抗击这一恶性骨肿瘤领域迈出了关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","03692","BK1191","BK1589"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654100808","title":"翰森制药(03692)：HS-20093治疗骨肉瘤III期临床研究达到主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2654100808","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654100808?lang=zh_cn&edition=full","pubTime":"2026-07-28 18:01","pubTimestamp":1785232902,"startTime":"0","endTime":"0","summary":"智通财经APP讯，翰森制药 公布，该集团自研B7-H3靶向抗体-药物偶联物HS-20093，在用于既往接受过至少二线系统治疗后进展或复发的骨肉瘤患者的关键性III期临床试验中达到主要终点。安全性特征与既往研究结果一致，未发现新的安全性信号。ARTEMIS-011研究详细数据预计未来在国际肿瘤学术大会上予以公布。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1473155.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","BK1589","03692","III","BK4134","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654700022","title":"里昂：翰森制药维持“跑赢大市”评级 目标价升至42港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2654700022","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654700022?lang=zh_cn&edition=full","pubTime":"2026-07-28 10:20","pubTimestamp":1785205200,"startTime":"0","endTime":"0","summary":"模拟交易客户端里昂发布研报称，维持翰森制药2026至2028年盈利预测不变，目标价由40港元升至42港元，维持“跑赢大市”评级，预期翰森明年将有5款新药获批上市，包括B7-H3 ADC、Olatorepatide、c-MET及RET等，可为2028年及以后的可持续盈利增长奠定基础。在2027年密集的新产品上市浪潮、商务拓展的持续交付以及产品管线的稳步推进支撑下，里昂预测翰森制药2026至2028年收入可分别增长14%、10%及14%，净利润则将分别增长9%、12%及16%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/hkgg/2026-07-28/doc-inikimee8154158.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["EWH","03692"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654458022","title":"【券商聚焦】交银国际：下半年医药板块有望迎来修复 但内部分化或持续加大","url":"https://stock-news.laohu8.com/highlight/detail?id=2654458022","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654458022?lang=zh_cn&edition=full","pubTime":"2026-07-28 10:01","pubTimestamp":1785204072,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际表示，近一个月恒生医疗保健指数涨17.4%，跑赢大市。其中，生物药、CXO及处方药板块表现较优于其他板块。机构持仓方面，2026年年中以来，内资持仓延续提升态势，而外资则略有降低。该机构指，中报季临近，7月以来多家公司业绩预告陆续发布，CXO板块表现亮眼，业绩和订单延续高增长态势。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250109/MjJmNDVlM2IxNTc1MzAyMDFjYTFhODQyNzEzMTQ0NzU5OA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MjJmNDVlM2IxNTc1MzAyMDFjYTFhODQyNzEzMTQ0NzU5OA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1986903","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03692","06160","LU1720050803.USD","LU2097828714.EUR","LU2476274308.USD","LU0856984785.SGD","HK0000320223.HKD","06078","01177","01548","01952","LU0417516571.SGD","06990","01951","09996","BK1521","01276","01801","BK1219","LU0572944931.SGD","KURE","02162","06821","02268","LU1813983027.USD","01530","09966","06996","LU2399975544.HKD","02269","02596","01093","02273","09926","159938","09939","LU1880383366.USD","KCE","LU0588546209.SGD","LU0348783233.USD","03329","02096","03759","LU2039709279.SGD","LU0634319403.HKD","LU2328871848.SGD","HK0000165453.HKD","00013","BK1587","LU0196878994.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654735092","title":"里昂：升翰森制药(03692.HK)目标价至42港元 料明年多种新药上市可支持盈利增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2654735092","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654735092?lang=zh_cn&edition=full","pubTime":"2026-07-27 14:23","pubTimestamp":1785133439,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1589","03692","BK1583","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653184027","title":"重药控股与翰森制药正式启动新丰翼项目战略合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2653184027","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653184027?lang=zh_cn&edition=full","pubTime":"2026-07-23 11:07","pubTimestamp":1784776020,"startTime":"0","endTime":"0","summary":"南方财经7月23日电，据重药控股消息，7月22日，重药控股与翰森制药集团有限公司召开新丰翼项目签约会。根据协议，本次项目合作将覆盖重庆、河南、陕西、贵州、四川、甘肃、天津、宁夏、湖北9个省市。双方将整合自身优质资源，在市场准入、新兴业务等重点合作领域持续深化协同，打造产销一体化创新合作体系。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607233818638391.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607233818638391.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1589","BK1191","BK1583","000950","03692","BK0250","BK0071"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653378262","title":"国金证券：口服环肽成药性验证元年 百亿美元赛道启幕","url":"https://stock-news.laohu8.com/highlight/detail?id=2653378262","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653378262?lang=zh_cn&edition=full","pubTime":"2026-07-22 09:15","pubTimestamp":1784682933,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，国金证券发布研报称，口服环肽是继GLP-1之后多肽领域最具确定性的前瞻布局方向，建议重点关注在该领域具备核心平台技术与临床管线的领先企业。国金证券主要观点如下：成药性验证跨越，口服环肽范式正式确立2026年口服环肽赛道完成从\"科学概念\"到\"产业现实\"的关键跃迁，成药性被彻底验证。产业资本正以真金白银验证平台价值：2026年YTD全球环肽BD交易总额达61.7亿美元创历史新高。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1470683.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1589","BK0012","BK1583","BK1191","BK0276","BK0028","03692","BK0183","BK0188","BK0201","600109"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134287176","title":"异动解读｜翰森制药盘中下跌3.33%，报32.1港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1134287176","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1134287176?lang=zh_cn&edition=full","pubTime":"2026-07-21 10:14","pubTimestamp":1784600073,"startTime":"0","endTime":"0","summary":"7月21日，翰森制药盘中下跌3.33%，报32.1港元/股，成交额7063.65万港元。翰森制药所在的制药行业中，板块整体走弱，个股中，石药集团跌1.88%，中国生物制药跌2.13%，恒瑞医药跌3.57%，凯莱英跌0.08%，先声药业跌0.46%。翰森制药集团有限公司是一家主要从事药品研发、生产及销售的投资控股公司，创新药产品主要应用于抗肿瘤、抗感染、中枢神经系统疾病、代谢及其他治疗领域。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03692"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110687072","title":"异动解读｜翰森制药盘中上涨3.08%，制药板块集体回暖叠加近期多重利好支撑","url":"https://stock-news.laohu8.com/highlight/detail?id=1110687072","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1110687072?lang=zh_cn&edition=full","pubTime":"2026-07-20 09:59","pubTimestamp":1784512765,"startTime":"0","endTime":"0","summary":"7月20日，翰森制药盘中上涨3.08%，报32.62港元/股，成交额7988.15万港元。制药板块整体走强，石药集团涨3.83%，凯莱英涨3.41%，东阳光药涨3.36%，恒瑞医药涨3.0%，中国生物制药涨2.41%。多重研发及出海进展叠加板块回暖，推动股价反弹。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03692"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":0.0965},{"period":"1month","weight":0.0814},{"period":"3month","weight":-0.0461},{"period":"6month","weight":-0.0843},{"period":"1year","weight":-0.011},{"period":"ytd","weight":-0.0366}],"compareEarnings":[{"period":"1week","weight":-0.0028},{"period":"1month","weight":0.0729},{"period":"3month","weight":-0.0156},{"period":"6month","weight":-0.0487},{"period":"1year","weight":0.0434},{"period":"ytd","weight":0.012}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"翰森制药集团有限公司是一家主要从事一系列药品的研发、生产及销售的投资控股公司。该公司的创新药产品包括阿美乐、豪森昕福、迈灵达、孚来美、恒沐、昕越、圣罗莱等产品。该公司的创新药产品主要应用于抗肿瘤、抗感染、中枢神经系统（CNS）疾病、代谢及其他治疗领域。该公司主要在国内市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.714286,"avgChangeRate":-0.002557},{"month":2,"riseRate":0.428571,"avgChangeRate":-0.012842},{"month":3,"riseRate":0.428571,"avgChangeRate":0.023369},{"month":4,"riseRate":0.571429,"avgChangeRate":0.033966},{"month":5,"riseRate":0.571429,"avgChangeRate":-0.005203},{"month":6,"riseRate":0.571429,"avgChangeRate":0.039397},{"month":7,"riseRate":0.625,"avgChangeRate":0.011389},{"month":8,"riseRate":0.75,"avgChangeRate":0.025758},{"month":9,"riseRate":0.571429,"avgChangeRate":-0.033022},{"month":10,"riseRate":0.142857,"avgChangeRate":0.0016},{"month":11,"riseRate":0.714286,"avgChangeRate":0.063448},{"month":12,"riseRate":0.571429,"avgChangeRate":0.016866}],"exchange":"SEHK","name":"翰森制药","nameEN":"HANSOH PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"翰森制药(03692)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供翰森制药(03692)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"翰森制药,03692,翰森制药股票,翰森制药股票老虎,翰森制药股票老虎国际,翰森制药行情,翰森制药股票行情,翰森制药股价,翰森制药股市,翰森制药股票价格,翰森制药股票交易,翰森制药股票购买,翰森制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"翰森制药(03692)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供翰森制药(03692)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}